Skip to content

Comparing Two Homeopathic Approaches for Psoriasis: Individualized homeopathic medicines vs Arsenicum Iodatum

Effectiveness of Individualized Homoeopathic Medicines as compared to Arsenicum Iodatum in the management of Psoriasis: An open label randomized controlled clinical trial - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/12/077516
Enrollment
60
Registered
2024-12-02
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L400- Psoriasis vulgaris

Interventions

Intervention1: Arsenicum Iodatum: Arsenicum Iodatum will be prescribed in centesimal potencies following the principles of homoeopathy. The dosage and frequency of repetition will be adjusted based on

Sponsors

Dr Asha Sharma
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients suffering from mild to moderate (PASI less than 7, to PASI 7 to 15,) psoriasis for 3 months or more. 2.Both male and female patient of Age group between 18 to 65 years (Married & Unmarried), irrespective of their race, caste, religion and socioeconomic status. 3. Patient willing to give voluntary written informed consent.

Exclusion criteria

Exclusion criteria: 1.Suffering from severe psoriasis (PASI greater than 15, independent of DLQI score) 2.Suffering from guttate, pustular, erythrodermic and annular varieties of psoriasis 3.Similar looking skin conditions – atopic and contact dermatitis, lichen planus, secondary syphilis, mycosis fungoides, tinea corporis, pityriasis rosea, etc. 4.Vulnerable population – unconscious, non-ambulatory, too sick for consultation, differently abled, terminally or critically ill subjects. 5.Diagnosed cases of unstable mental or psychiatric illness or other uncontrolled or life-threatening illness affecting quality of life or any organ failure 6.Pregnant and puerperal women, lactating mothers. 7.Any other form(s) of substance abuse and/or dependence. 8.Self-reported immune-compromised state (e.g., HIV) 9.Unwilling to take part and not giving consent to join the study.

Design outcomes

Primary

MeasureTime frame
To assess the change in symptoms and severity in psoriasis area severity index (PASI) in Psoriasis patients after giving homoeopathic medicinesTimepoint: PASI will be calculated at every 1 month.

Secondary

MeasureTime frame
To assess the change in quality of life by using DLQI questionnaire in Psoriasis patients after giving homoeopathic medicinesTimepoint: DLQI will be calculated at every 1 month.

Countries

India

Contacts

Public ContactDr Asha Sharma

Dr B R Sur Homoeopathic Medical College, Hospital & Research Centre

neenamehan@gmail.com9811578570

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026